



## Frequently Asked Questions

---

### Baxter Acquisition of Baxa Corporation

Baxter International, Inc. has completed its acquisition of Baxa Corporation.

#### **Why did Baxter acquire Baxa Corporation?**

Baxter and Baxa are both dedicated to improving patient care through innovative drug preparation and delivery technology. The addition of Baxa's product line will complement Baxter's own robust portfolio of multi-chamber container technology, base solutions and fluid therapy. In addition, Baxa's pharmacy automation and dose management technology allows hospital pharmacists to ensure timely delivery of safe doses. With these new offerings, we will be able to offer a broad array of solutions to meet patients' nutritional requirements while increasing operational efficiency in the pharmacy.

#### **How does this deal affect my business with Baxa Corporation?**

There will be no immediate changes to product lines, services or to how we are structured. We will continue to deliver the high level of service, support and quality you expect. For the immediate future, Baxa will continue as the legal entity with which you will do business. Orders will come from Baxa Corporation or one of its affiliates and Baxa will honor all existing purchase orders and contracts. If the naming strategy for the business changes, you will receive adequate advance notice.

#### **Will Baxa be integrated into Baxter or will it be a separately run subsidiary?**

At this time, our current organization structure will operate as it has been. Over time, it is expected that Baxa will be integrated into Baxter.

#### **Do I need to negotiate a new contract with Baxter to cover my products and services to Baxa?**

All current contracts remain in effect. You do not need to negotiate a new one.

#### **Who do I contact regarding the purchase of my products or services?**

Please continue to work with your Baxa purchasing and supply chain contacts for questions related to Baxa business, and your Baxter supply chain representative for Baxter-related questions.

#### **Will my terms and/or agreements change under Baxter ownership?**

Our business relationship, terms and agreements remain in effect. Baxa will continue to honor all of its contracts. Suppliers are expected to continue to meet the same quality and regulatory requirements in place prior to the acquisition.

**What changes can I anticipate regarding my existing contracts or purchase orders? Who do I contact if I have questions?**

There will be no immediate changes to your contract or purchase orders. Further, there will be no immediate changes to how materials are provided to Baxa (consignment, replenishment, etc.). We will notify you in advance of any future changes that may impact our business, with complete instructions. If you have any questions, contact your Baxa supply chain representative.

**I currently do business with both Baxter and Baxa, who should I contact?**

Please contact the same purchasing, supply chain or logistics individuals that you currently work with at each company.

**What changes can I anticipate regarding my existing transportation agreements? Who do I contact regarding our current services?**

There will be no immediate changes to your agreements. If you have any questions, contact your Baxa supply chain specialist.

**Should I contact Baxter to let them know my capabilities?**

Please continue to work with the same purchasing, supply chain or logistics individuals that you currently work with at each company. We will communicate any changes that affect our operations as soon as they become available.

For more information, please see the press release announcement at [www.baxa.com/newsandevents](http://www.baxa.com/newsandevents) or visit [www.baxter.com](http://www.baxter.com). Please direct any inquiries about Baxa and this agreement to Dennis Schneider at 303-400-2841 ([dennis.schneider@baxa.com](mailto:dennis.schneider@baxa.com)) or to Marian Robinson at 303.617.2157 ([marian.robinson@baxa.com](mailto:marian.robinson@baxa.com)).

*This document includes forward-looking statements concerning agreements entered into between Baxter and Baxa, including expectations with respect to the closing of the transaction. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; product quality or patient safety issues; failure to obtain the necessary consents or to satisfy other closing conditions; and other risks identified in the company's most recent filing on Form 10-K and other SEC filings, all of which are available on the company's website. The company does not undertake to update its forward-looking statements.*